Yahoo Finance EN

Hutchmed price target lowered to $21 from $22 at BofA

Mar 07, 2026 &03160707202631; 13:16 UTC finance.yahoo.com Trending 3/5

Read original on finance.yahoo.com ↗

↘

Negative for markets

Sentiment score: -35/100

Moderate impact Short-term (days)

WHAT THIS MEANS

Bank of America lowered Hutchison China MediTech's (Hutchmed) price target from $22 to $21 per share, indicating a modest downward revision of analyst expectations. This 4.5% reduction suggests cautious sentiment toward the Chinese pharmaceutical company's near-term prospects.

AI CONFIDENCE

65% High

SENTIMENT GAUGE

NEWS POWER SCORE

AFFECTED ASSETS

↓

HUTCHISON CHINA MEDITECH

HUTCHISON CHINA MEDITECHStock

Expected to decline

Price target reduction by major investment bank signals lower expected valuation and potential downside risk in near term

PRICE HISTORY

Loading chart...

⚡ SUGGESTED ACTION

Consider reducing long positions or avoiding new entries until the stock stabilizes around the new $21 target. Monitor for additional analyst downgrades that could accelerate the decline further.

KEY SIGNALS

Analyst downgradePrice target reductionNegative momentum signalPotential profit-taking opportunity

SECTORS INVOLVED

HealthcarePharmaceuticalsBiotechnology

Analysis generated on Mar 09, 2026 at 17:47 UTC

Disclaimer: This analysis is generated by artificial intelligence for informational purposes only and does not constitute financial advice, investment recommendation, or solicitation. Original reporting by Yahoo Finance. Always conduct your own research and consult a qualified financial advisor before making investment decisions.

Hutchmed price target lowered to $21 from $22 at BofA

RELATED INTELLIGENCE